Andrew Farrington

Securities Enforcement

• A leading investment bank and capital markets firm in several SEC insider trading inquiries, specifically focused on life sciences investments.
• A leading global investment adviser in an SEC investigation related to the accuracy of certain financial, risk and related-party disclosures for one of its managed-funds.
• A publicly traded chemical and materials company in an SEC inquiry related to the calculation and disclosure of certain financial metrics.
• A private energy company and its founder and CEO in an SEC investigation related to certain securities offerings.
• A former finance executive of a public software company in an SEC investigation concerning revenue recognition practices.
• A leading investment adviser focused on the digital economy in an SEC investigation related to the accuracy of certain portfolio company valuations and adequacy of disclosures to limited partners.
• A former controller of a public healthcare company in litigation against the SEC involving allegations of accounting fraud.*
• An individual investor and his investment companies in an SEC investigation related to broker-dealer registration.*

Internal Investigations

• A global investment adviser in an internal investigation involving allegations of improper calculation of incentive fees and securities law violations.
• A major industrial equipment company in an internal investigation involving allegations of improper revenue recognition practices.

Civil Litigation

• Power & Digital Infrastructure Acquisition Corporation (XPDI) and its directors and officers in fiduciary duty litigation arising from XPDI’s $4.3 billion de-SPAC merger with Core Scientific, Inc.
• AIM ImmunoTech Inc. and its board of directors in expedited fiduciary duty litigation arising from AIM’s defense against a hostile takeover attempt. 

*Prior to joining Kirkland